Prescott Group Capital Management, L.L.C. Affimed N.V. Transaction History

Prescott Group Capital Management, L.L.C.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 10, 2019	SELL	$3.05 - $4.34 $581,574 - $827,551	-190,680 Closed	0 $0
Q4 2018 Feb 11, 2019	BUY	$2.82 - $4.67 $74,673 - $123,661	26,480 Added 16.13%	190,680 $593,000
Q3 2018 Nov 09, 2018	BUY	$1.45 - $6.15 $238,090 - $1.01 Million	164,200 New	164,200 $714,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Prescott Group Capital Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Prescott Group Capital Management, L.L.C. with notifications on news.